---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-019243"
form_type: "8-K"
ticker: "ELUT"
cik: "0001708527"
company_name: "ELUTIA INC."
filed_at: "2023-11-20T23:59:59+00:00"
generated_at: "2026-06-07T23:25:37.317129+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Elutia recasts 2022 financials to reflect sale of Orthobiologics business as discontinued operations

## Summary
- Completed sale of Orthobiologics business to Berkeley Biologics LLC on November 8, 2023 for an undisclosed amount.
- Asset Purchase Agreement with Berkeley dated September 17, 2023 triggered discontinued operations classification.
- Historical results of Orthobiologics business reclassified as discontinued operations in recast 2022 Form 10-K.
- Company now operates three segments: Device Protection, Women's Health, and Cardiovascular after sale.

## SEC filing metadata
- accession: 0001558370-23-019243
- form_type: 8-K
- ticker: ELUT
- cik: 0001708527
- company_name: ELUTIA INC.
- filed_at: 2023-11-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708527/000155837023019243/0001558370-23-019243-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708527/000155837023019243/elut-20231120x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-019243
- JSON: https://secwatch.observer/filing/0001558370-23-019243.json
- Plain text: https://secwatch.observer/filing/0001558370-23-019243.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.